The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
Shaji Kumar
Consultant or Advisory Role - Celgene; Merck
Honoraria - Merck
Research Funding - Celgene; Genzyme; Millennium; Novartis
William Bensinger
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium; Onyx
Research Funding - Array BioPharma; AstraZeneca; Celgene; Genentech; Millennium; Onyx
Craig B. Reeder
Research Funding - Celgene; Millennium; Novartis
Todd M. Zimmerman
Consultant or Advisory Role - Novartis
Honoraria - Celgene; Millennium
James R. Berenson
Consultant or Advisory Role - Celgene; Medtronic; Millennium; Novartis; Onyx
Honoraria - Celgene; Medtronic; Millennium; Novartis; Onyx
Research Funding - Genentech; Merck
Guohui Liu
Employment or Leadership Position - Millennium
Deborah Berg
Employment or Leadership Position - Millennium
Neeraj Gupta
Employment or Leadership Position - Millennium
Alessandra Di Bacco
Employment or Leadership Position - Millennium
Ai-Min Hui
Employment or Leadership Position - Millennium
Ruben Niesvizky
Consultant or Advisory Role - Celgene; Millennium; Onyx
Research Funding - Celgene; Millennium; Onyx